Safety and Efficacy of RRG001 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 12, 2023

Primary Completion Date

April 15, 2026

Study Completion Date

December 31, 2030

Conditions

Neovascular Age-related Macular Degeneration

Interventions

DRUG

RRG001

Administered via Subretinal injection. Dosage form: injection solution.

Trial Locations (1)

RECRUITING

Tianjin Medical University Eye Hospital, Tianjin

All Listed Sponsors

lead

Shanghai Refreshgene Technology Co., Ltd.

INDUSTRY